Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Hyping TH

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Nov 19, 2021 1:26pm

174 Views

Post# 34146560

RE:RE:Hyping TH

While I am not familiar with that person/show, I can still say that the best program for TH executives to be interviewed on, at least in regards to having a positive impact on the share price, would be CNBC or Fox Business channel. Or maybe something like 60 Minutes, but that is not likely.

jfm1330 wrote: The best program to really explain it fully would be Decouverte. I guess it will happen if they have great results on humans.

Mitchbeaude wrote:
I would have preferred an interview with Grald Fillion of Radio-Canada. It is a much more serious economic program with a facilitator who knows the economy well. Also Grald Filion knows the company Theratechnologie. He could have ask much more relevant questions.